공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

EpiCast Report : 만성폐쇄성폐질환(COPD) - 역학 예측(-2023년)

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

리서치사 GlobalData
발행일 2019년 12월 상품 코드 347928
페이지 정보 영문 38 Pages
가격
US $ 3,995 ₩ 4,576,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,152,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 13,728,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


EpiCast Report : 만성폐쇄성폐질환(COPD) - 역학 예측(-2023년) Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028
발행일 : 2019년 12월 페이지 정보 : 영문 38 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

만성폐쇄성폐질환(COPD)은 호흡 곤란이나 숨참, 천명, 흉부 압박감 등의 증상을 일으키는 질환으로, 세계보건기구(WHO)에 의하면 2030년까지 사인 3위에 오를 것이라 합니다. 세계 8대 시장에서 COPD 이환 건수는 2013년 약 6,423만건에서 연평균 1.49% 증가해 2023년에는 7,380만건에 이를 것으로 예측됩니다.

만성폐쇄성폐질환(COPD: Chronic Obstructive Pulmonary Disease)의 개요와 위험인자, 세계 8 대 시장의 동향, 향후의 역학적 예측 등을 정리하여 전해드립니다.

제1장 목차

제2장 서론

제3장 역학

  • 질환의 배경
  • 위험인자와 병존질환
  • 세계적 동향
    • 미국
    • 유럽 5개국
    • 일본 및 호주
  • 예측 방법
    • 이용한 정보 출처
    • 이용하지 않은 정보 출처
    • 예측 방법과 전제조건
  • 역학적 예측
    • 이환 건수
    • 연령별 이환 건수
    • 성별 이환 건수
    • 연령표준화 건수
    • 중증도별 건수
    • 진단 건수
    • 연령별 진단 건수
    • 성별 진단 건수
    • 연령표준화 진단 건수
    • 중증도별 진단 건수
    • 병존질환이 있는 진단 건수
    • 1년 생존 진단 건수
  • 고찰
    • 역학적 예측
    • 분석의 한계
    • 분석의 강점

제4장 부록

도표

LSH 16.01.15

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for COPD

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years, 2018 and 2028
  • Figure 3: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 4: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
  • Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
  • Figure 8: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 9: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 10: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 11: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 12: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 13: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 14: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 15: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 16: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms. The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017). Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for COPD was based on symptoms and the results of spirometry testing. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. GlobalData epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in GlobalData's forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope

  • The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ≥35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
  • The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
  • Understand magnitude of COPD population by severity at diagnosis.

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Chronic Obstructive Pulmonary Disease (COPD): Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for COPD (2018-2028)
    • 3.5.1 Total Prevalent Cases of COPD
    • 3.5.2 Sex-Specific Total Prevalent Cases of COPD
    • 3.5.3 Age-Specific Total Prevalent Cases of COPD
    • 3.5.4 Diagnosed Prevalent Cases of COPD
    • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.7 Diagnosed Prevalent Cases of COPD by Severity
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top
전화 문의
F A Q